Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/112101
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbbott, R.en
dc.contributor.authorChang, D.en
dc.contributor.authorEyre, H.en
dc.contributor.authorBousman, C.en
dc.contributor.authorMerrill, D.en
dc.contributor.authorLavretsky, H.en
dc.date.issued2018en
dc.identifier.citationAmerican Journal of Geriatric Psychiatry, 2018; 26(2):125-133en
dc.identifier.issn1064-7481en
dc.identifier.issn1545-7214en
dc.identifier.urihttp://hdl.handle.net/2440/112101-
dc.description.abstractClinicians still employ a "trial-and-error" approach to optimizing treatment regimens for late-life depression (LLD). With LLD affecting a significant and growing segment of the population, and with only about half of older adults responsive to antidepressant therapy, there is an urgent need for a better treatment paradigm. Pharmacogenetic decision support tools (DSTs), which are emerging technologies that aim to provide clinically actionable information based on a patient's genetic profile, offer a promising solution. Dozens of DSTs have entered the market in the past 15 years, but with varying level of empirical evidence to support their value. In this clinical review, we provide a critical analysis of the peer-reviewed literature on DSTs for major depression management. We then discuss clinical considerations for the use of these tools in treating LLD, including issues related to test interpretation, timing, and patient perspectives. In adult populations, newer generation DSTs show promise for the treatment of major depression. However, there are no primary clinical trials in LLD cohorts. Independent and comparative clinical trials are needed.en
dc.description.statementofresponsibilityRyan Abbott, Donald D. Chang, Harris A. Eyre, Chad A. Bousman, David A. Merrill, Helen Lavretskyen
dc.language.isoenen
dc.publisherElsevieren
dc.subjectDepression; decision support tool; genetic testing; geriatric; late-life depression; pharmacogenomic; precision medicineen
dc.titlePharmacogenetic decision support tools: a new paradigm for late-life depression?en
dc.typeJournal articleen
dc.identifier.rmid0030085549en
dc.identifier.doi10.1016/j.jagp.2017.05.012en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1127700en
dc.identifier.pubid396427-
pubs.library.collectionPharmacology publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.